Tuesday, December 08, 2020 11:21:27 PM
https://www.businesswire.com/news/home/20201208005955/en/Takeda%E2%80%99s-Pipeline-Has-Potential-to-Contribute-Significantly-to-Revenue-Growth-Over-Next-Decade
Recent TAK News
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder • PR Newswire (US) • 04/23/2024 11:00:00 AM
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs • PR Newswire (US) • 04/22/2024 08:10:00 AM
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease • Business Wire • 04/18/2024 11:00:00 PM
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food • Business Wire • 04/08/2024 12:00:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:56:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:53:00 PM
- Takeda annonce les candidats au conseil d’administration pour la prochaine assemblée générale des actionnaires • Business Wire • 03/27/2024 05:01:00 AM
- Takeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekannt • Business Wire • 03/27/2024 05:01:00 AM
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting • Business Wire • 03/26/2024 11:07:00 PM
- 第148回定時株主総会に提案する取締役候補者について • Business Wire • 03/26/2024 11:07:00 PM
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) • Business Wire • 03/26/2024 12:00:00 PM
- 武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®(ポナチニブ)の医薬品承認事項変更申請(sNDA)について、FDAからの承認取得を発表 • Business Wire • 03/21/2024 01:39:00 PM
- Takeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch die FDA bei erwachsenen Patienten mit neu diagnostizierter Ph+ ALL • Business Wire • 03/21/2024 07:33:00 AM
- Takeda annonce l'approbation par la FDA des États-Unis d'une demande supplémentaire de nouveau médicament (sNDA) pour ICLUSIG ® (ponatinib) chez les patients adultes atteints de leucémie lymphoblastique aiguë (LAL Ph+) nouvellement diagnostiquée • Business Wire • 03/20/2024 07:18:00 PM
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL • Business Wire • 03/19/2024 04:20:00 PM
- CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders • GlobeNewswire Inc. • 03/19/2024 10:30:54 AM
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia • Business Wire • 03/13/2024 12:00:00 PM
- 武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力 • Business Wire • 02/28/2024 12:03:00 PM
- Takeda et Biological E. Limited s’associent pour accélérer l’accès au vaccin contre la dengue dans les zones endémiques • Business Wire • 02/27/2024 10:26:00 PM
- Takeda und Biological E. Limited arbeiten zusammen, um den Zugang zu Dengue-Impfstoff in endemischen Gebieten zu beschleunigen • Business Wire • 02/27/2024 12:38:00 PM
- Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas • Business Wire • 02/27/2024 04:30:00 AM
- Championing Rare Voices on Rare Disease Day • PR Newswire (Canada) • 02/26/2024 12:00:00 PM
- Faire entendre sa voix à l'occasion de la Journée des maladies rares • PR Newswire (Canada) • 02/26/2024 12:00:00 PM
- FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) • Business Wire • 02/12/2024 01:00:00 PM
- Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 • Business Wire • 02/08/2024 11:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM